« Older Entries
LSP led a EURO 32 million investement in OxThera AB
Friday, December 9th, 2016
Amsterdam, the Netherlands, December 9, 2016, OxThera AB, a Stockholm-based privately-held biopharmaceutical company, uses the proceeds to complete the Oxabact® development program for treatment of Primary hyperoxalu [...]
Impacting patient lives with new diabetes drug approval
Tuesday, November 22nd, 2016
Amsterdam, Munich, Boston, November 22, 2016 - LSP (Life Sciences Partners), the European life sciences investment group, today announces the FDA approval of SoliquaTM 100/33 for the treatment of adults with type 2 di [...]
« Older Entries